Inhaled Corticosteroids and COVID-19 Risk and Mortality: A Nationwide Cohort Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choi, Jae Chol | - |
dc.contributor.author | Jung, Sun-Young | - |
dc.contributor.author | Yoon, Una A. | - |
dc.contributor.author | You, Seung-Hun | - |
dc.contributor.author | Kim, Myo-Song | - |
dc.contributor.author | Baek, Moon Seong | - |
dc.contributor.author | Jung, Jae-Woo | - |
dc.contributor.author | Kim, Won-Young | - |
dc.date.accessioned | 2023-03-08T13:02:24Z | - |
dc.date.available | 2023-03-08T13:02:24Z | - |
dc.date.issued | 2020-11 | - |
dc.identifier.issn | 2077-0383 | - |
dc.identifier.issn | 2077-0383 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/63171 | - |
dc.description.abstract | Inhaled corticosteroids (ICS) could increase both the risk of coronavirus disease 2019 (COVID-19) and experiencing poor outcomes. To compare the clinical outcomes between ICS users and nonusers, COVID-19-related claims in the Korean Health Insurance Review and Assessment database were evaluated. To evaluate susceptibility to COVID-19 among patients with COPD or asthma, a nested case-control study was performed using the same database. In total, 7341 patients were confirmed to have COVID-19, including 114 ICS users and 7227 nonusers. Among 5910 patients who were hospitalized, death was observed for 9% of ICS users and 4% of nonusers. However, this association was not significant when adjusted for age, sex, region, comorbidities, and hospital type (aOR, 0.94; 95% CI, 0.43-2.07). The case-control analysis of COPD compared 640 cases with COVID-19 to 2560 matched controls without COVID-19, and the analysis of asthma compared 90 cases with COVID-19 to 360 matched controls without COVID-19. Use of ICS was not significantly associated with COVID-19 among patients with COPD (aOR, 1.02; 95% CI, 0.46-2.25) or asthma (aOR, 0.38; 95% CI, 0.13-1.17). Prior ICS use was not significantly associated with COVID-19 in patients with COPD or asthma, nor with clinical outcomes among patients with COVID-19. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | MDPI | - |
dc.title | Inhaled Corticosteroids and COVID-19 Risk and Mortality: A Nationwide Cohort Study | - |
dc.type | Article | - |
dc.identifier.doi | 10.3390/jcm9113406 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL MEDICINE, v.9, no.11 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.wosid | 000593326000001 | - |
dc.identifier.scopusid | 2-s2.0-85100725999 | - |
dc.citation.number | 11 | - |
dc.citation.title | JOURNAL OF CLINICAL MEDICINE | - |
dc.citation.volume | 9 | - |
dc.type.docType | Article | - |
dc.publisher.location | 스위스 | - |
dc.subject.keywordAuthor | asthma | - |
dc.subject.keywordAuthor | chronic obstructive pulmonary disease | - |
dc.subject.keywordAuthor | COVID-19 | - |
dc.subject.keywordAuthor | SARS-CoV-2 | - |
dc.subject.keywordAuthor | steroids | - |
dc.subject.keywordPlus | OBSTRUCTIVE PULMONARY-DISEASE | - |
dc.subject.keywordPlus | ASTHMA | - |
dc.subject.keywordPlus | PREVALENCE | - |
dc.subject.keywordPlus | PNEUMONIA | - |
dc.subject.keywordPlus | ALPHA | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.